{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:06Z","timestamp":1786119366184,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"DOI":"10.1097\/qad.0b013e328339e274","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T21:48:53Z","timestamp":1273182533000},"page":"1291-1298","source":"Crossref","is-referenced-by-count":17,"title":["Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens"],"prefix":"10.1097","volume":"24","author":[{"given":"Marisa","family":"Tungsiripat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia El","family":"Bejjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"O'Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison C","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrilynn","family":"Hileman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Storer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Harrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A","family":"McComsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/00002030-200104130-00025","article-title":"The impact of experiencing lipodystrophy on the sexual behaviour and well being among HIV-infected homosexual men","volume":"15","author":"Dukers","year":"2001","journal-title":"AIDS"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002030-200501030-00002","article-title":"Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine","volume":"19","author":"McComsey","year":"2005","journal-title":"AIDS"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1086\/593179","article-title":"Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction","volume":"198","author":"Mallon","year":"2008","journal-title":"J Infect Dis"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/135965350701200610","article-title":"Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes","volume":"12","author":"Viengchareun","year":"2007","journal-title":"Antivir Ther"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antivir Ther"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/518005","article-title":"A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy","volume":"195","author":"Cavalcanti","year":"2007","journal-title":"J Infect Dis"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","article-title":"Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)","volume":"13","author":"Slama","year":"2008","journal-title":"Antivir Ther"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial","volume":"143","author":"van Wijk","year":"2005","journal-title":"Ann Intern Med"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00002030-200303280-00022","article-title":"Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy","volume":"17","author":"Calmy","year":"2003","journal-title":"AIDS"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1310\/hct0904-254","article-title":"Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone","volume":"9","author":"Macallan","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e328339e274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:22:36Z","timestamp":1786040556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201006010-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328339e274","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6,1]]}}}